Quadrant Capital Group LLC Has $1.76 Million Position in Novartis AG (NYSE:NVS)

Quadrant Capital Group LLC lifted its position in Novartis AG (NYSE:NVS) by 2.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,100 shares of the company’s stock after acquiring an additional 352 shares during the period. Quadrant Capital Group LLC’s holdings in Novartis were worth $1,761,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Legacy Investment Solutions LLC acquired a new stake in Novartis in the third quarter worth $28,000. Human Investing LLC acquired a new stake in Novartis during the 4th quarter worth $25,000. Union Bancaire Privee UBP SA bought a new position in Novartis during the fourth quarter worth about $27,000. Kestra Investment Management LLC acquired a new position in Novartis in the fourth quarter valued at about $47,000. Finally, Clearstead Trust LLC bought a new stake in shares of Novartis in the fourth quarter worth about $51,000. Institutional investors own 13.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on NVS shares. Morgan Stanley assumed coverage on Novartis in a report on Wednesday, February 12th. They set an “underweight” rating on the stock. StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 8th. Barclays restated an “underweight” rating on shares of Novartis in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft raised shares of Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. Finally, UBS Group reissued a “neutral” rating on shares of Novartis in a research note on Thursday, February 13th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $123.38.

Novartis Stock Down 5.8 %

Shares of NVS stock opened at $105.79 on Friday. The firm’s fifty day moving average price is $109.02 and its two-hundred day moving average price is $106.98. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92. The firm has a market capitalization of $216.24 billion, a P/E ratio of 17.99, a PEG ratio of 1.70 and a beta of 0.56.

Novartis (NYSE:NVS) last released its earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, equities analysts predict that Novartis AG will post 8.45 EPS for the current fiscal year.

Novartis Announces Dividend

The business also recently disclosed a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were issued a $3.8695 dividend. The ex-dividend date was Wednesday, March 12th. Novartis’s payout ratio is presently 42.69%.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.